Home  |  Contact

UniProtKB/Swiss-Prot Q9UBP0: Variant p.Gly377Glu

Spastin
Gene: SPAST
Variant information

Variant position:  377
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Glutamate (E) at position 377 (G377E, p.Gly377Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SPG4.
Any additional useful information about the variant.



Sequence information

Variant position:  377
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  616
The length of the canonical sequence.

Location on the sequence:   IVILPSLRPELFTGLRAPAR  G LLLFGPPGNGKTMLAKAVAA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Mouse                         IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Rat                           IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Pig                           IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Bovine                        IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Chicken                       IVILPSLRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Xenopus laevis                IVILPSIRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Xenopus tropicalis            IVILPSIRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAA

Zebrafish                     IVILPALRPELFTGLRAPARGLLLFGPPGNGKTMLAKAVAM

Caenorhabditis elegans        AVILPALNPNLFKGLRQPVKGILLFGPPGNGKTLLAKAVAG

Drosophila                    MVILPSVRPELFTGLRAPAKGLLLFGPPGNGKTLLARAVAT

Slime mold                    SVILPNLRPDVFTGLRAPPKGLLLFGPPGNGKTMIAKAVAY

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 616 Spastin
Topological domain 78 – 616 Cytoplasmic
Region 228 – 616 Sufficient for microtubule severing
Mutagenesis 388 – 388 K -> A. Abrogates ATPase activity and abolishes microtubule severing.
Beta strand 376 – 386


Literature citations

Detection of novel mutations and review of published data suggests that hereditary spastic paraplegia caused by spastin (SPAST) mutations is found more often in males.
Proukakis C.; Moore D.; Labrum R.; Wood N.W.; Houlden H.;
J. Neurol. Sci. 306:62-65(2011)
Cited for: VARIANTS SPG4 MET-364; LEU-368; GLU-377 AND SER-450;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.